Breast Cancer Patients Sought for Study of Premature Menopause

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 11
Volume 7
Issue 11

NEW YORK--Memorial Sloan-Kettering Cancer Center and the Wake Forest University School of Medicine are seeking women recently diagnosed with breast cancer for a study of the determinants of premature menopause and its effects on quality of life. Jeanne Petrek, MD, is the principal investigator.

NEW YORK--Memorial Sloan-Kettering Cancer Center and the Wake Forest University School of Medicine are seeking women recently diagnosed with breast cancer for a study of the determinants of premature menopause and its effects on quality of life. Jeanne Petrek, MD, is the principal investigator.

No blood or urine samples will be collected for this study, and patients can participate entirely through the mail. Women will fill out questionnaires and menstrual cycle diaries for the duration of the study--2½ years. Follow-up questionnaires will be sent every 6 months from the original date of enrollment, and new menstrual diaries every 3 months.

To be eligible, women must be between the ages of 18 and 45; must have been diagnosed with stage I, II, or III breast cancer in the past 8 months; and must be having regular menstrual cycles at the time of diagnosis.

For more information, please contact Joanna Winawer, research coordinator, toll-free at 877-636-7562, or by e-mail: winawer@mskcc.org.

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.